Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 226) Show all publications
Levin, N. K., Mårtensson, J., Björkman, L., Venge, P., Klingberg, E., Deminger, A., . . . Forsblad-d'elia, H. (2026). Increased blood levels of neutrophil- and platelet-derived markers in patients with radiographic axial spondyloarthritis: a pilot study. Rheumatology International, 46, Article ID 55.
Open this publication in new window or tab >>Increased blood levels of neutrophil- and platelet-derived markers in patients with radiographic axial spondyloarthritis: a pilot study
Show others...
2026 (English)In: Rheumatology International, ISSN 0172-8172, E-ISSN 1437-160X, Vol. 46, article id 55Article in journal (Refereed) Published
Abstract [en]

A challenge in diagnosing and monitoring radiographic axial spondyloarthritis (r-axSpA) is the absence of reliable biomarkers. This cross-sectional pilot study aimed to evaluate platelet- and neutrophil-derived substances as potential biomarkers in r-axSpA, given the involvement of these cells in disease pathology. Serum and plasma were collected from 13 male, HLA-B27-positive r-axSpA patients without disease-modifying anti-rheumatic drugs and 13 age- and sex-matched blood donor controls. Concentrations of platelet-derived soluble CD40 ligand (sCD40L) and soluble P-selectin (sP-selectin) and neutrophil-derived human neutrophil lipocalin (HNL), myeloperoxidase (MPO), and galectin-3 were measured using ELISA. Associations between these markers and clinical parameters, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were assessed by Spearman's rank correlation. Group differences were analysed using the Wilcoxon signed-rank test. Median concentrations of serum sCD40L (4.2 vs. 2.7 ng/mL; p = 0.001), plasma HNL (23.7 vs. 18.6 mg/L; p = 0.040), serum HNL (74.7 vs. 52.3 mg/L; p = 0.013), and plasma MPO (56.6 vs. 37.3 mg/L; p = 0.027) were significantly higher in r-axSpA patients compared with controls. Plasma HNL correlated positively with CRP and ESR, but not with other clinical parameters. In both patients and controls, serum concentrations of sCD40L, sP-selectin, HNL, and MPO were significantly higher than their plasma counterparts, highlighting differences related to sample processing. Serum sCD40L, serum and plasma HNL, and plasma MPO were elevated in r-axSpA patients compared with controls. These findings warrant validation in larger cohorts to clarify the role of sCD40L, HNL and MPO across a heterogeneous group of patients with early and established r-axSpA.

Place, publisher, year, edition, pages
Springer Nature, 2026
Keywords
Ankylosing spondylitis, Myeloperoxidase, CD40 ligand, P-selectin, Neutrophils, Blood platelets
National Category
Immunology in the Medical Area
Identifiers
urn:nbn:se:uu:diva-582470 (URN)10.1007/s00296-026-06090-8 (DOI)001703157200001 ()41758355 (PubMedID)2-s2.0-105031588202 (Scopus ID)
Funder
Magnus Bergvall Foundation, 2024 − 1434Wilhelm och Martina Lundgrens Vetenskapsfond, 2024-SA-4605Swedish Rheumatism Association, R-1013370Swedish Rheumatism Association, R-76701Åke Wiberg Foundation, M24-0227Swedish Society of Medicine, SLS-324011
Available from: 2026-03-18 Created: 2026-03-18 Last updated: 2026-03-18Bibliographically approved
Ling Lundström, M., Peterson, C., Amcoff, D., Lampinen, M., Hjortswang, H., Bergemalm, D., . . . Carlson, M. (2026). The Utility of Faecal Biomarkers in the Discrimination Between Acute Gastroenteritis and Inflammatory Bowel Disease. Biomedicines, 14(9), Article ID 1951.
Open this publication in new window or tab >>The Utility of Faecal Biomarkers in the Discrimination Between Acute Gastroenteritis and Inflammatory Bowel Disease
Show others...
2026 (English)In: Biomedicines, E-ISSN 2227-9059, Vol. 14, no 9, article id 1951Article in journal (Refereed) Published
Abstract [en]

Background: Acute infectious gastroenteritis (GE) and inflammatory bowel disease (IBD) may have similar clinical characteristics at onset, and discrimination between these two diagnoses can initially be challenging. Aim: To explore faecal biomarkers reflecting neutrophil, eosinophil, and epithelial activity to distinguish between acute GE and IBD onset. Methods: Faecal samples were collected from patients presenting with acute GE (n = 28), treatment-na & iuml;ve patients with newly diagnosed IBD (n = 40), and healthy controls, HC (n = 40). Faecal biomarkers, including faecal calprotectin (FC), myeloperoxidase (MPO), human neutrophil lipocalin (HNL), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN), were assessed by ELISA. The Kruskal-Wallis test was used for biomarker comparisons. To evaluate the discriminative capability of biomarkers, receiver operating characteristic (ROC) curves were established. Result: Patients with acute GE displayed elevated levels of all the tested biomarkers compared with HC (p < 0.001). Higher levels of faecal HNL (p < 0.001), EDN (p < 0.01), and MPO (p < 0.05) were seen in acute GE patients than in patients with newly diagnosed IBD. HNL yielded the highest discriminative capability between acute GE and IBD with AUC 0.74, 95%CI: 0.62-0.84. Conclusions: This exploratory study suggests that faecal biomarkers may provide complementary information in the differentiation of patients with suspected acute GE and new-onset IBD. Our findings indicate that faecal HNL may have the ability to distinguish between these conditions. However, given the exploratory design and limited sample size, findings should be interpreted with caution, and the discriminative value of HNL and the other biomarkers requires further validation in larger, well-characterised acute GE cohorts.

Place, publisher, year, edition, pages
MDPI, 2026
Keywords
IBD, gastroenteritis, faecal biomarker
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-601839 (URN)10.3390/biomedicines14091951 (DOI)001893149800001 ()42792694 (PubMedID)2-s2.0-105052786023 (Scopus ID)
Funder
Swedish Foundation for Strategic Research, RB13-016Swedish Research Council, 2020-02021
Available from: 2026-10-23 Created: 2026-10-23 Last updated: 2026-10-23Bibliographically approved
Álvez, M. B., Bergström, S., Kenrick, J., Johansson, E., Åberg, M., Akyildiz, M., . . . Uhlén, M. (2025). A human pan-disease blood atlas of the circulating proteome. Science, 390(6779), Article ID eadx2678.
Open this publication in new window or tab >>A human pan-disease blood atlas of the circulating proteome
Show others...
2025 (English)In: Science, ISSN 0036-8075, E-ISSN 1095-9203, Vol. 390, no 6779, article id eadx2678Article in journal (Refereed) Published
Abstract [en]

The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. Here, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and BMI, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8,262 individuals and up to 5,416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.

Place, publisher, year, edition, pages
American Association for the Advancement of Science (AAAS), 2025
National Category
Medical Biotechnology
Identifiers
urn:nbn:se:uu:diva-569491 (URN)10.1126/science.adx2678 (DOI)001643421200001 ()41066540 (PubMedID)2-s2.0-105025246161 (Scopus ID)
Available from: 2025-10-14 Created: 2025-10-14 Last updated: 2026-10-30Bibliographically approved
Venge, P., Tejera, V. C., Peterson, C., Xu, S., Larsson, A., Simrén, M., . . . Törnblom, H. (2024). Elevated Fecal Biomarkers of Colo-Rectal Epithelial Cell Activity in Irritable Bowel Syndrome.. Neurogastroenterology and Motility, Article ID e14984.
Open this publication in new window or tab >>Elevated Fecal Biomarkers of Colo-Rectal Epithelial Cell Activity in Irritable Bowel Syndrome.
Show others...
2024 (English)In: Neurogastroenterology and Motility, ISSN 1350-1925, E-ISSN 1365-2982, article id e14984Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastro-intestinal disorder characterized by discomfort with constipation and/or diarrhea with unclear pathophysiology. We aimed to determine the activities of colorectal eosinophils, neutrophils and epithelial cells by biomarkers in feces reflecting these activities.

METHODS: Fecal samples were collected from 185 patients with IBS before and after 8 weeks of placebo or mesalazine treatment and from 40 healthy subjects. Calprotectin, eosinophil derived neurotoxin (EDN), eosinophil cationic protein (ECP), human neutrophil lipocalin (HNL) (pab/765) or dimer, human phospholipase BII-precursor (HPLBII-P) and myeloperoxidase (MPO) were measured by ELISA. Symptom scores were evaluated by diaries.

RESULTS: HPLBII-P, HNL (pab/765) and EDN, proteins secreted by intestinal epithelial cells, were elevated in IBS patients as compared to healthy subjects (p < 0.0001-p = 0.008). In contrast, the neutrophil proteins calprotectin, MPO and HNL dimer were unaltered. The eosinophilic protein ECP was lower in IBS (p = 0.001). HNL (pab/765) (p = 0.01) and EDN (p = 0.004) increased in IBS patients after mesalazine treatment. Colo-rectal mucosa showed strong staining of HPLBII-P and western blotting of fecal extracts showed the presence of mainly monomeric, epithelial-associated HNL.

CONCLUSIONS: The absence of signs of involvement of neutrophils and eosinophils in IBS suggests that activity of local epithelial cells rather than inflammation may be a major determinant of the disease. The measurements of EDN, HNL (pab/765), and HPLBII-P may serve as potential fecal biomarkers in the study and monitoring of IBS.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
calprotectin, eosinophil, eosinophil cationic protein, eosinophil derived neurotoxin, human neutrophil lipocalin, myeloperoxidase, neutrophil
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-545816 (URN)10.1111/nmo.14984 (DOI)001379626700001 ()39688084 (PubMedID)
Available from: 2024-12-23 Created: 2024-12-23 Last updated: 2025-03-05Bibliographically approved
Ling Lundström, M., Peterson, C., Hedin, C. R., Bergemalm, D., Lampinen, M., Magnusson, M. K., . . . Carlson, M. (2024). Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD. Alimentary Pharmacology and Therapeutics, 60(6), 765-777
Open this publication in new window or tab >>Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD
Show others...
2024 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 60, no 6, p. 765-777Article in journal (Refereed) Published
Abstract [en]

Background: Faecal biomarkers can be used to assess inflammatory bowel disease (IBD).

Aim: To explore the performance of some promising biomarkers in diagnosing and predicting disease course in IBD.

Methods: We included 65 patients with treatment-naïve, new-onset Crohn's disease (CD), 90 with ulcerative colitis (UC), 67 symptomatic controls (SC) and 41 healthy controls (HC) in this prospective observational study. We analysed faecal samples for calprotectin (FC), myeloperoxidase (MPO), human neutrophil lipocalin (HNL), eosinophil cationic protein ECP and eosinophil-derived neurotoxin (EDN) and compared markers among groups. We assessed the diagnostic capability of biomarkers with receiver operating characteristic curves. Clinical disease course was determined for each patient with IBD and analysed the association with biomarkers by logistic regression.

Results: All markers were elevated at inclusion in patients with IBD compared with HC (p < 0.001) and SC (p < 0.001). FC (AUC 0.85, 95% CI: 0.79-0.89) and MPO (AUC 0.85, 95% CI: 0.80-0.89) showed the highest diagnostic accuracy in distinguishing IBD from SC. The diagnostic ability of biomarkers differed between IBD subtypes with the highest performance for FC and MPO in CD. The diagnostic accuracy was further improved by combining FC and MPO (p = 0.02). Levels of FC, MPO and HNL at inclusion were predictive of an aggressive disease course with MPO showing the strongest association (p = 0.006).

Conclusions: This study provides new insight into the diagnostic and prognostic capability of neutrophil and eosinophil biomarkers in IBD and suggests that MPO, alone or in combination with FC, may add to the diagnostic power of faecal biomarkers.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-535182 (URN)10.1111/apt.18154 (DOI)001270545300001 ()38997818 (PubMedID)2-s2.0-85198503570 (Scopus ID)
Funder
Swedish Research Council, 2020–02021
Available from: 2024-07-17 Created: 2024-07-17 Last updated: 2025-06-16Bibliographically approved
Venge, P., Peterson, C., Xu, S., Larsson, A., Johansson, J. & Tydén, J. (2024). HNL Dimer in plasma is a unique and useful biomarker for the monitoring of antibiotic treatment in sepsis. PLOS ONE, 19(9), Article ID e0310987.
Open this publication in new window or tab >>HNL Dimer in plasma is a unique and useful biomarker for the monitoring of antibiotic treatment in sepsis
Show others...
2024 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 19, no 9, article id e0310987Article in journal (Refereed) Published
Abstract [en]

Introduction: Sepsis is a growing problem worldwide and associated with high mortality and morbidity. The early and accurate diagnosis and effective supportive therapy are critical for combating mortality. The aim of the study was to compare the kinetics of four biomarkers in plasma in patients admitted to ICU including sepsis and during antibiotics treatment.

Methods: The biomarkers evaluated were HBP (Heparin-binding protein), HNL Dimer (Human Neutrophil Lipocalin), HNL Total and PCT (Procalcitonin). Plasma was obtained at admission to ICU and during follow-up at days 2 and 3. Antibiotic treatment was started or reviewed on admission to ICU. The results were compared to SOFA and KDIGO-scores and to survival. 277 patients admitted to ICU were included of which 30% had sepsis. The other groups were categorized as miscellaneous, other medical and trauma.

Results: The plasma concentrations of all four biomarkers were highly elevated with the highest concentrations in sepsis patients. During the follow-up period HNL Dimer decreased already day 2 and further so day 3 (p<0.00001) in contrast to unchanged concentrations of the other three biomarkers. HNL Total showed the strongest relationships to the clinical scores (p<0.0001) and was by multiples regression analysis independently related to these scores.

Conclusion: Our data supports and confirms our earlier findings of HNL Dimer being a novel and potentially useful clinical tool in antibiotic stewardship in sepsis. HNL Total reflects epithelial cell activity in the body and is an interesting biomarker for the management of organ failure in such patients.

Place, publisher, year, edition, pages
Public Library of Science (PLoS), 2024
National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-539361 (URN)10.1371/journal.pone.0310987 (DOI)001320777500042 ()39325799 (PubMedID)
Available from: 2024-09-27 Created: 2024-09-27 Last updated: 2024-11-07Bibliographically approved
Venge, P., Xu, S., Peterson, C., Eriksson, A.-K., Hultström, M., Larsson, A., . . . Frithiof, R. (2024). Plasma Biomarkers Associated to Outcome in Patients with Sars-Cov-2 Infection. Journal of Clinical and Laboratory Medicine, 7(1)
Open this publication in new window or tab >>Plasma Biomarkers Associated to Outcome in Patients with Sars-Cov-2 Infection
Show others...
2024 (English)In: Journal of Clinical and Laboratory Medicine, E-ISSN 2572-9578, Vol. 7, no 1Article in journal (Refereed) Published
Abstract [en]

Background: A serious consequence of respiratory infections with SARS-CoV-2 is Acute Kidney Injury (AKI). The aim of this study was to evaluate some novel biomarkers measured in plasma for their associations with the outcome of this infection as to AKI and mortality.

Methods: Four different HNL (Human Neutrophil Lipocalin) assays were constructed using different antibody configurations, reflecting both neutrophil and epithelial cell activities. TK-1 (Thymidine kinase-1) was measured as a sign of cell destruction and proliferation. For comparison the plasma concentrations of NGAL (Neutrophil Gelatinase Associated Lipocalin), the cytokines IL-6, IL-8 and IFN-γ and of cystatin C, and procalcitonin were also measured. One hundred and three patients with severe respiratory failure admitted to the ICU were sampled for blood at admittance and at day three (n=67) after admittance.

Results: Sixty-five percent of the patients developed AKI. The performance of the HNL assay 763/8F was most closely associated to outcome as to AKI and mortality with Area Under the Receiver Operating Characteristics Curve (AUC) of 0.87 and a sensitivity of 80% and a specificity of 88% in COVID-19 patients with and without severe AKI (p<0.0001). TK-1 was significantly related to the development of AKI (p=0.01) and the three cytokines were related to mortality (p=0.004-p<0.001).

Conclusion: The HNL variant 763/8F and TK-1 are novel biomarkers that might become useful and novel tools in the management of COVID-19 patients, but likely also in other patients affected by AKI. 

Place, publisher, year, edition, pages
Sci Forschen, Inc., 2024
National Category
Anesthesiology and Intensive Care
Identifiers
urn:nbn:se:uu:diva-527343 (URN)10.16966/2572-9578.141 (DOI)
Funder
Swedish Research Council, 2014-02569Swedish Research Council, 2014-07606The Swedish Kidney Foundation, F2020-0054
Available from: 2024-04-29 Created: 2024-04-29 Last updated: 2025-11-04Bibliographically approved
Xu, S., Hultström, M., Larsson, A., Lipcsey, M., Lindskog, C., Bülow, S., . . . Venge, P. (2024). The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Glomerular Activity in COVID-19 and Diabetes Mellitus. Journal of Clinical Medicine, 13(9), Article ID 2540.
Open this publication in new window or tab >>The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Glomerular Activity in COVID-19 and Diabetes Mellitus
Show others...
2024 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 13, no 9, article id 2540Article in journal (Refereed) Published
Abstract [en]

Background: The human phospholipase B-II precursor (HPLBII-P) was originally purified from white blood cells but is also found in other cellular structures, such as kidney glomeruli and tubuli. The objective of this report was to investigate the relationship of HPLBII-P in urine to acute kidney injury in patients with COVID-19. Methods: Urine was collected at admission from 132 patients with COVID-19 admitted to the intensive care units (ICUs) because of respiratory failure. HPLBII-P was measured using a sensitive ELISA. For comparison, human neutrophil lipocalin (HNL) was measured in urine, using the ELISA configured with the monoclonal antibody 763/8F, as a sign of tubular affection in addition to routine biomarkers of kidney disease. Results: Overall, the concentrations of urinary HPLBII-P were almost 3-fold higher in patients with COVID-19 compared to healthy controls (p < 0.0001) and with significantly higher concentrations even in patients with COVID-19 without signs of acute kidney injury (AKI) (p < 0.001). HPLBII-P was further increased in patients with AKI (p < 0.02). HPLBII-P was significantly increased in patients with diabetes mellitus (p = 0.0008) and correlated to plasma glucose (r = 0.29, p = 0.001) and urine albumin concentrations (r = 0.55, p < 0.001). Conclusions: Urine concentrations of HPLBII-P are highly raised in the urine of patients with COVID-19 and relate to AKI and diabetes mellitus. HPLBII-P may reflect glomerular injury and/or increased glomerular cell activity in SARS-CoV-2 infections.

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
KIM-1, NGAL, acute kidney injury (AKI), cystatin C, lipocalin
National Category
Infectious Medicine Anesthesiology and Intensive Care
Identifiers
urn:nbn:se:uu:diva-527862 (URN)10.3390/jcm13092540 (DOI)001221550100001 ()38731071 (PubMedID)
Available from: 2024-05-12 Created: 2024-05-12 Last updated: 2024-05-27Bibliographically approved
Xu, S., Larsson, A., Lind, L., Lindskog, C., Ärnlöv, J. & Venge, P. (2024). The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus?. Journal of Clinical Medicine, 13(9), Article ID 2629.
Open this publication in new window or tab >>The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus?
Show others...
2024 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 13, no 9, article id 2629Article in journal (Refereed) Published
Abstract [en]

Background: A previous report showed that the urine output of HPLBII-P in patients with diabetes mellitus and SARS-CoV-2 infection was increased as a sign of glomerular dysfunction. The aim of this report was to investigate the relation of the urine output of HPLBII-P to diabetes mellitus in two large community-based elderly populations, i.e., the ULSAM and PIVUS cohorts. Methods: HPLBII-P was measured by an ELISA in the urine of a community-based cohort of 839 men (ULSAM) collected at 77 years of age and in the urine of a community-based cohort of 75-year-old men, n = 387, and women, n = 401 (PIVUS). KIM-1, NGAL, and albumin were measured in urine and cathepsin S and cystatin C in serum. Results: HPLBII-P was significantly raised among males with diabetes in the ULSAM (p < 0.0001) and PIVUS cohorts (p ≤ 0.02), but not in the female cohort of PIVUS. In the female subpopulation of insulin-treated diabetes, HPLBII-P was raised (p = 0.02) as compared to women treated with oral antidiabetics only. In the ULSAM cohort, HPLBII-P was correlated to NGAL, KIM-1, and albumin in urine both in non-DM (all three biomarkers; p < 0.0001) and in DM (NGAL; p = 0.002, KIM-1; p = 0.02 and albumin; p = 0.01). Plasma glucose and HbA1c in blood showed correlations to U-HPLBII-P (r = 0.58, p < 0.001 and r = 0.42, p = 0.004, respectively). U-HPLBII-P and cathepsin S were correlated in the ULSAM group (r = 0.50, p < 0.001). No correlations were observed between U-HPLBII-P and serum creatinine or cystatin C. Conclusions: The urine measurement of HPLBII-P has the potential to become a novel and useful biomarker in the monitoring of glomerular activity in diabetes mellitus.

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
biomarker, nephropathy, podocyte
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-527863 (URN)10.3390/jcm13092629 (DOI)001220542000001 ()38731158 (PubMedID)
Available from: 2024-05-12 Created: 2024-05-12 Last updated: 2024-05-27Bibliographically approved
Ling Lundström, M., Peterson, C., Lampinen, M., Hedin, C. R. H., Keita, Å. V., Kruse, R., . . . Carlson, M. (2023). Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 14(8), Article ID e00605.
Open this publication in new window or tab >>Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease
Show others...
2023 (English)In: Clinical and Translational Gastroenterology, E-ISSN 2155-384X, Vol. 14, no 8, article id e00605Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: 

Fecal calprotectin (FC) is a noninvasive tool for examining response to biologics in inflammatory bowel disease (IBD), but its performance in relation to other novel fecal markers of various cellular origins is unknown.

METHODS: 

We performed a prospective multicenter cohort study and included patients with active IBD who provided a fecal sample at initiation of biological therapy. Levels of FC, myeloperoxidase (MPO), human neutrophil lipocalin (HNL), and eosinophil-derived neurotoxin (EDN) were analyzed and related to clinical remission status at 3 months. Changes in levels of markers at 3 months were calculated, and the impact of concomitant use of corticosteroids at baseline was estimated.

RESULTS: 

In patients achieving clinical remission (n = 27), a decrease in levels of FC (P = 0.005), MPO (P < 0.001), HNL (P < 0.001), and EDN (P < 0.001) was observed, whereas no significant decrease was seen in patients not achieving remission (n = 39). There was a significant difference in the change in the level of MPO (P = 0.01) and HNL (P = 0.02) between patients achieving clinical remission and those who did not, but changes in FC and EDN could not differentiate between these groups. Patients with concomitant systemic corticosteroids at inclusion had lower levels of HNL (P = 0.01) and EDN (P < 0.001) at baseline, compared with patients without corticosteroids.

DISCUSSION: 

Fecal MPO, HNL, and EDN are all promising biomarkers for assessing the treatment outcome of biologics in patients with IBD. Fecal levels of EDN and HNL are significantly affected by corticosteroids indicating a greater sensitivity to the effects of corticosteroids compared with levels of FC and MPO.

Place, publisher, year, edition, pages
Wolters Kluwer, 2023
Keywords
inflammatory bowel disease, fecal biomarkers, biological therapy
National Category
Gastroenterology and Hepatology Immunology in the medical area
Identifiers
urn:nbn:se:uu:diva-524612 (URN)10.14309/ctg.0000000000000605 (DOI)001158085800005 ()37256716 (PubMedID)
Funder
Swedish Foundation for Strategic Research, RB13-016Uppsala University
Available from: 2024-03-11 Created: 2024-03-11 Last updated: 2025-02-11Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-5863-790x

Search in DiVA

Show all publications